171 related articles for article (PubMed ID: 23953217)
41. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
[TBL] [Abstract][Full Text] [Related]
42. Antipsychotic treatment and mortality in schizophrenia.
Torniainen M; Mittendorfer-Rutz E; Tanskanen A; Björkenstam C; Suvisaari J; Alexanderson K; Tiihonen J
Schizophr Bull; 2015 May; 41(3):656-63. PubMed ID: 25422511
[TBL] [Abstract][Full Text] [Related]
43. Comparing acute toxicity of first- and second-generation antipsychotic drugs: a 10-year, retrospective cohort study.
Ciranni MA; Kearney TE; Olson KR
J Clin Psychiatry; 2009 Jan; 70(1):122-9. PubMed ID: 19192473
[TBL] [Abstract][Full Text] [Related]
44. Clozapine and its protective effect on all-cause, natural, and suicide mortality in patients with schizophrenia: A nationwide cohort study in Taiwan.
Chen WY; Chen PH; Pan CH; Su SS; Tsai SY; Chen CC; Kuo CJ
Schizophr Res; 2024 Jun; 268():150-160. PubMed ID: 37479588
[TBL] [Abstract][Full Text] [Related]
45. A prospective study on the pattern of medication use for schizophrenia in the outpatient pharmacy department, Hospital Tengku Ampuan Rahimah, Selangor, Malaysia.
Ponto T; Ismail NI; Abdul Majeed AB; Marmaya NH; Zakaria ZA
Methods Find Exp Clin Pharmacol; 2010; 32(6):427-32. PubMed ID: 20852752
[TBL] [Abstract][Full Text] [Related]
46. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.
Volavka J; Citrome L
Expert Opin Pharmacother; 2009 Aug; 10(12):1917-28. PubMed ID: 19558339
[TBL] [Abstract][Full Text] [Related]
47. [Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone].
Bret P; Bonnet F; Bret MC; Jaffré A
Encephale; 2002; 28(4):329-42. PubMed ID: 12232542
[TBL] [Abstract][Full Text] [Related]
48. Ethnic comparisons of antipsychotic use in schizophrenia.
Wheeler A; Humberstone V; Robinson E
Aust N Z J Psychiatry; 2008 Oct; 42(10):863-73. PubMed ID: 18777230
[TBL] [Abstract][Full Text] [Related]
49. Does switching to another antipsychotic in patients with clozapine-associated granulocytopenia solve the problem? Case series of 18 patients.
Coşar B; Taner ME; Eser HY; Altınöz AE; Tarhan R
J Clin Psychopharmacol; 2011 Apr; 31(2):169-73. PubMed ID: 21346615
[TBL] [Abstract][Full Text] [Related]
50. Influence of antipsychotics on mortality in schizophrenia: systematic review.
Weinmann S; Read J; Aderhold V
Schizophr Res; 2009 Aug; 113(1):1-11. PubMed ID: 19524406
[TBL] [Abstract][Full Text] [Related]
51. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study.
Yang SY; Kao Yang YH; Chong MY; Yang YH; Chang WH; Lai CS
Clin Pharmacol Ther; 2007 Apr; 81(4):586-94. PubMed ID: 17235331
[TBL] [Abstract][Full Text] [Related]
52. Long-term use of antipsychotics among community-dwelling persons with Alzheimer׳s disease: A nationwide register-based study.
Koponen M; Taipale H; Tanskanen A; Tolppanen AM; Tiihonen J; Ahonen R; Hartikainen S
Eur Neuropsychopharmacol; 2015 Oct; 25(10):1706-13. PubMed ID: 26233607
[TBL] [Abstract][Full Text] [Related]
53. Mortality and use of psychotropic medication in sleep apnoea patients: a population-wide register-based study.
Jennum P; Baandrup L; Tønnesen P; Ibsen R; Kjellberg J
Sleep Med; 2018 Mar; 43():19-24. PubMed ID: 29482806
[TBL] [Abstract][Full Text] [Related]
54. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland.
Taipale H; Solmi M; Lähteenvuo M; Tanskanen A; Correll CU; Tiihonen J
Lancet Psychiatry; 2021 Oct; 8(10):883-891. PubMed ID: 34474013
[TBL] [Abstract][Full Text] [Related]
55. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study.
Danielsson B; Collin J; Jonasdottir Bergman G; Borg N; Salmi P; Fastbom J
Br J Clin Pharmacol; 2016 Apr; 81(4):773-83. PubMed ID: 26574175
[TBL] [Abstract][Full Text] [Related]
56. 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia.
Tiihonen J; Tanskanen A; Taipale H
Am J Psychiatry; 2018 Aug; 175(8):765-773. PubMed ID: 29621900
[TBL] [Abstract][Full Text] [Related]
57. Description of long-term polypharmacy among schizophrenia outpatients.
Suokas JT; Suvisaari JM; Haukka J; Korhonen P; Tiihonen J
Soc Psychiatry Psychiatr Epidemiol; 2013 Apr; 48(4):631-8. PubMed ID: 23007295
[TBL] [Abstract][Full Text] [Related]
58. Causes of death in clozapine-treated patients in a catchment area: a 10-year retrospective case-control study.
Rose E; Chen S; Turrion C; Jenkins C; Cardinal RN; Fernandez-Egea E
Eur Neuropsychopharmacol; 2020 Jul; 36():160-166. PubMed ID: 32546415
[TBL] [Abstract][Full Text] [Related]
59. Antipsychotics as a method of suicide: population based follow-up study of suicide in Northern Finland.
Mainio A; Kuusisto L; Hakko H; Riipinen P
Nord J Psychiatry; 2021 May; 75(4):281-285. PubMed ID: 33215967
[TBL] [Abstract][Full Text] [Related]
60. Transformation of excess mortality in people with schizophrenia and bipolar disorder in Taiwan.
Pan YJ; Yeh LL; Chan HY; Chang CK
Psychol Med; 2017 Oct; 47(14):2483-2493. PubMed ID: 28443526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
